Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Significant Growth in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APREGet Rating) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 1,170,000 shares, a growth of 22.0% from the May 15th total of 959,100 shares. Based on an average trading volume of 449,600 shares, the short-interest ratio is currently 2.6 days. Currently, 7.1% of the shares of the stock are short sold.

NASDAQ:APRE opened at $0.79 on Friday. The stock’s fifty day moving average is $1.15 and its 200 day moving average is $1.97. Aprea Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $5.89. The firm has a market capitalization of $17.40 million, a PE ratio of -0.48 and a beta of 0.39.

Aprea Therapeutics (NASDAQ:APREGet Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.02. As a group, analysts anticipate that Aprea Therapeutics will post -1.64 earnings per share for the current fiscal year.

Several analysts have recently issued reports on the company. Royal Bank of Canada decreased their price objective on Aprea Therapeutics from $5.00 to $4.00 and set a “sector perform” rating on the stock in a report on Wednesday, March 16th. HC Wainwright decreased their price objective on Aprea Therapeutics from $4.00 to $2.00 and set a “neutral” rating on the stock in a report on Wednesday, March 16th. Two equities research analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. According to MarketBeat.com, Aprea Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.25.

A number of hedge funds have recently added to or reduced their stakes in APRE. Gyon Technologies Capital Management LP purchased a new stake in Aprea Therapeutics in the first quarter worth $38,000. Squarepoint Ops LLC purchased a new stake in Aprea Therapeutics in the fourth quarter worth $43,000. Magnus Financial Group LLC purchased a new stake in Aprea Therapeutics in the fourth quarter worth $98,000. Verition Fund Management LLC purchased a new stake in Aprea Therapeutics in the third quarter worth $103,000. Finally, Royal Bank of Canada increased its stake in Aprea Therapeutics by 39.4% in the second quarter. Royal Bank of Canada now owns 21,150 shares of the company’s stock worth $104,000 after purchasing an additional 5,977 shares during the period. Institutional investors and hedge funds own 16.46% of the company’s stock.

About Aprea Therapeutics (Get Rating)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.